Close Menu

Agendia

The companies aim to create new products enabling faster access to predictive information used in treatment planning for patients with breast cancer.

Myriad Genetics' EndoPredict, Agendia's MammaPrint (distributed in Germany by PathoNext), and Veracyte's Prosigna will now be covered by public insurance.

PathoNext will run Agendia's assays in its labs using next-generation sequencing and work with HiSS, Agendia's German distributor, to offer the tests to German patients.

Using MammaPrint to guide breast cancer chemo de-escalation could result in significant healthcare savings in five of six evaluated countries, according to the analysis.

The US DOJ alleged that the company conspired to "artificially delay" ordering its MammaPrint test in order to circumvent Medicare's 14-day rule.

At the American Society of Clinical Oncology's virtual meeting, investigators presented two new studies of BluePrint classification patterns.

News items for the in vitro diagnostics industry for the week of Dec. 30, 2019

MammaPrint classifies patients as either high risk or low risk of recurrence over a 10-year period while BluePrint classifies patients by breast cancer subtype.

Laboratory Corporation of American said this week that its Covance Drug Development segment will buy Envigo's nonclinical research services business, while Envigo's Research Models Services business will buy LabCorp's Covance Research Products business in a $485 million deal to be paid by LabCorp.

The group recommends Myriad Genetics' EndoPredict, NanoString's Prosigna, and Genomic Health's Oncotype DX tests for guiding chemotherapy decisions if certain conditions are met.

Pages